The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection
Christina M. Arieta, Yushu Joy Xie(BioNTech (United States)), Daniel Rothenberg(BioNTech (United States)), Huitian Diao(BioNTech (United States)), Dewi Harjanto(BioNTech (United States)), Shirisha Meda(BioNTech (United States)), Krisann Marquart(BioNTech (United States)), Byron Koenitzer(BioNTech (United States)), Tracey Sciuto(BioNTech (United States)), Alexander Lobo(BioNTech (United States)), Adam Zuiani(BioNTech (United States)), Stefanie A. Krumm(BioNTech (Germany)), Carla Iris Cadima Couto(BioNTech (Germany)), Stephanie Hein(BioNTech (Germany)), André P. Heinen(BioNTech (Germany)), Thomas Ziegenhals(BioNTech (Germany)), Yunpeng Liu-Lupo(BioNTech (United States)), Annette B. Vogel(BioNTech (Germany)), John R. Srouji(BioNTech (United States)), Stephanie Fesser(BioNTech (Germany)), Kaushik Thanki(BioNTech (Germany)), Kerstin C. Walzer(BioNTech (Germany)), Theresa A. Addona(BioNTech (United States)), Özlem Türeci, Uğur Şahin, Richard B. Gaynor(BioNTech (United States)), Asaf Poran
Cited by 89Open Access
Abstract
T cell responses to diverse epitopes in animal models, alone or when co-administered with BNT162b2 while preserving spike-specific immunity. Importantly, we demonstrate that BNT162b4 protects hamsters from severe disease and reduces viral titers following challenge with viral variants. These data suggest that a combination of BNT162b2 and BNT162b4 could reduce COVID-19 disease severity and duration caused by circulating or future variants. BNT162b4 is currently being clinically evaluated in combination with the BA.4/BA.5 Omicron-updated bivalent BNT162b2 (NCT05541861).
Related Papers
No related papers found
Powered by citation graph analysis